Physician profile
Ryan Butler
NPI 1194262261
$1,674.09
in general payments reported to CMS, 2019-2025
14 companies · $508 in 2025
The $508 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $37.59 · 2024: $1,128 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $316.63 | 2023-2025 | Trintellix |
| Abbvie INC. | $310.57 | 2024-2025 | |
| Corcept Therapeutics | $259.85 | 2024-2025 | Korlym |
| Pfizer INC. | $218.72 | 2024-2025 | |
| Lilly USA, LLC | $167.52 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Astellas Pharma US INC | $128.38 | 2024-2025 | Veozah |
| Novo Nordisk INC | $86.75 | 2024-2025 | Wegovy |
| Redhill Biopharma INC. | $46.93 | 2024 | Talicia |
| Boston Scientific Corporation | $39.35 | 2025 | Rhythmia Mapping System |
| Janssen Pharmaceuticals, INC | $29.99 | 2024-2025 | Spravato |
| Axsome Therapeutics, INC. | $20.67 | 2025 | Auvelity |
| Antares Pharma, INC. | $18.85 | 2024 | Xyosted |
| Esperion Therapeutics, INC. | $15.70 | 2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $14.18 | 2024 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.